CloneID: 1D10 (Hu1D10; Apolizumab)
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original mouse antibody 1D10 was generated by immunizing female BALB/c mice intraperitoneally with human large cell lymphoma HO-85. Humanized version of this antibody was generated by grafting CDRs of the parental mouse antibody onto human framework regions.
Buffer Composition: PBS only.
Uniprot Accession No.: P04233
Specificity Statement: This antibody recognizes a variant epitope on the beta chain of HLA-DR. It can bind some but not all HLA-DR beta chains. The antigen that this antibody binds is expressed on lymphocytes, macrophages, and dendritic (mesenchymal) cells and on most B cell neoplasms. HLA-DR is an MHC class II cell surface receptor encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31. HLA-DR is also involved in several autoimmune conditions, disease susceptibility and disease resistance. The primary function of HLA-DR is to present peptide antigens, potentially foreign in origin, to the immune system for the purpose of eliciting or suppressing T-(helper)-cell responses that eventually lead to the production of antibodies against the same peptide antigen.
Application Notes (Clone): This antibody is the humanized version of anti-HLA-DR mouse parental antibody called 1D10. This antibody is capable of recognizing a majority of B-cell malignancies. This antibody is capable of inducing complement-mediated cytotoxicity, antibody dependent cell cytotoxicity and direct apoptosis of B cells expressing HLA-DR. The original mouse version does not posses these characteristics. This antibody has similar affinity to human HLA-DR as compared to its parental mouse antibody (PMID: 11477560). This antibody was also used for the generation of a bispecific antibody in combination with anti-CD3e antibody M291 (Visilizumab) (US6129914).
English
Deutsch
